TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Description: PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.Measure: Progression-Free Survival (PFS) Time: Baseline up to 96 weeks
Description: Percentage of subjects achieving complete response (CR) and partial response (PR).Measure: Objective response rate (ORR) Time: Baseline up to 96 weeks
Description: OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.Measure: Overall survival (OS) Time: Baseline up to 96 weeks
Description: Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).Measure: Disease control rate（DCR） Time: Baseline up to 96 weeks
Single Group Assignment
There is one SNP
2.Has mutations in (epidermal growth factor receptor)EGFR, (anaplastic lymphoma kinase)ALK, (c-ros oncogene 1 receptor kinase)ROS1 or T790M and not resistant to targeted drug. --- T790M ---